Osteoprotegerin Levels in Primary Hyperparathyroidism: Effect of Parathyroidectomy and Association with Bone Metabolism

被引:0
作者
L. S. Stilgren
L. M. Hegedüs
H. Beck-Nielsen
B. Abrahamsen
机构
[1] Odense University Hospital,Dept. of Endocrinology
[2] DK-5000 Odense,undefined
来源
Calcified Tissue International | 2003年 / 73卷
关键词
OPG-PTH; Primary hyperparathyroidism; Bone turnover; BMD;
D O I
暂无
中图分类号
学科分类号
摘要
The effect of parathyroid hormone (PTH) on the production of osteoprotegerin (OPG) remains controversial. Most in vitro studies indicate that PTH decreases OPG secretion by the osteoblast, but in vivo observations are conflicting. In primary hyperparathyroidism (PHPT), hypersecretion of PTH leads to enhanced bone resorption and formation with increased risk of fracture. Patients with PHPT are cured by surgery, resulting in normalization of PTH levels and bone metabolism, but the concomitant effects on OPG production are not known. The hypothesis of the present study was that the circulating level of OPG is diminished in patients with PHPT and increases with successful parathyroidectomy. We also speculated that serum OPG may determine the magnitude of bone loss up to the time of surgery. In the present study, 20 patients (17 women and 3 men, mean age 62 y) with PHPT who were candidates for surgical cure were examined before and 12 months after surgery. Bone turnover markers decreased and BMD increased significantly after surgery. Serum OPG did not correlate with PTH before surgery (r = 0.07, P = 0.77) and was not affected by parathyroidectomy (P = 0.79). After normalization of PTH, bone formation markers showed significant (P1NP) and near-significant (osteocalcin) correlations with serum OPG. In conclusion, serum OPG is not decreased in patients with PHPT, nor is serum OPG to any demonstrable extent regulated by PTH pre- or postoperatively.
引用
收藏
页码:210 / 216
页数:6
相关论文
共 95 条
[1]  
O’Brien EA(2000)Osteoprotegerin ligand regulates osteoclast adherence to the bone surface in mouse calvaria. Biochem Biophys Res Commun 274 281-290
[2]  
Williams JH(1998)Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 165-176
[3]  
Marshall MJ(1999)Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J Immunol 163 434-442
[4]  
Lacey DL(1999)Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96 3540-3545
[5]  
Timms E(1998)Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95 3597-3602
[6]  
Tan HL(1997)Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 309-319
[7]  
Kelley MJ(1998)Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139 1329-1337
[8]  
Dunstan CR(1998)Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids. J Endocrinol 159 191-195
[9]  
Burgess T(2000)In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. J Bone Miner Res 15 863-871
[10]  
Jimi E(2000)Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors. J Bone Miner Res 15 1766-1775